Related Experiment Video
Updated: Jan 4, 2026
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
IL-37 Plays a Beneficial Role in Patients with Acute Coronary Syndrome
Xiaobo Mao1, Ruirui Zhu1, Fangyuan Zhang2
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Insights
Interleukin-37 (IL-37) helps restore immune balance in acute coronary syndrome (ACS) patients by expanding regulatory T cells (Tregs) and suppressing inflammatory Th1/Th17 cells. IL-37-treated dendritic cells show therapeutic potential for ACS.
Area of Science:
- Immunology
- Cardiovascular Medicine
Background:
- Interleukin-37 (IL-37) is an immune inhibitor.
- The role of IL-37 in acute coronary syndrome (ACS) is not fully understood.
Purpose of the Study:
- To investigate the role of IL-37 in ACS patients.
- To explore the therapeutic potential of IL-37 and IL-37-treated dendritic cells (tDCs) in ACS.
Main Methods:
- Classified patients into normal coronary artery (NCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI) groups.
- Measured circulating Treg, Th1, and Th17 frequencies.
- Assessed IL-37 effects on peripheral blood mononuclear cells (PBMCs) and dendritic cells (DCs), including Treg expansion and DC stability.
Main Results:
- ACS patients showed decreased Tregs and increased Th1/Th17 cells.
- IL-37 expanded Tregs and suppressed Th1/Th17 cells in ACS PBMCs.
- IL-37-treated DCs exhibited a stable tolerogenic phenotype, promoting Treg expansion and reducing Th1/Th17 cells.
Conclusions:
- IL-37 plays a beneficial role in ACS.
- Autologous IL-37-treated tDCs represent a potential novel therapeutic strategy for ACS.
Background:
Interleukin-37 (IL-37) acts as an inhibitor of innate and adaptive immunity. However, the exact role of IL-37 in the patients with acute coronary syndrome (ACS) remains to be elucidated.
Methods:
Patients were classified into 4 groups: normal coronary artery (NCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). The circulating Treg, Th1, and Th17 frequencies were measured. The effect of IL-37 on stimulated peripheral blood mononuclear cells (PBMCs) and the influence of IL-37 on DCs were explored. In addition, the role of IL-37-treated tDCs on Treg cell expansion and the stability of these tDCs were also tested.
Results:
Our results showed that the circulating Treg frequencies were decreased, while Th1 and Th17 frequencies were increased in ACS patients, and that IL-37 expanded Tregs but suppressed Th1 and Th17 cells in activated PBMCs derived from ACS patients. Of note, IL-37-treated human DCs obtained a tolerogenic phenotype, and such tDCs promoted expansion of Tregs and decreased the Th1 and Th17 populations when cocultured with CD4+ T cells. Interestingly, IL-37-treated DCs from patients with ACS are phenotypically and functionally comparable to IL-37-treated DCs from NCA patients, and tolerogenic properties of IL-37-treated DCs were highly stable.
Conclusion:
In conclusion, our results reveal a beneficial role of IL-37 in the patients with ACS and suggest that autologous IL-37-treated tDCs may be a novel therapeutic strategy for the patients with ACS.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:14Myocarditis III: Medical Management
01:26Acute Coronary Syndrome V: Nursing Management